Vimarsana
Biggest News Aggregation in the World

Page 30 - Human Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Human Use Today - Breaking & Trending Today

Allecra Therapeutics receives FDA approval for treatment targeting severe UTIs - Vimarsana News

Allecra Therapeutics receives FDA approval for treatment targeting severe UTIs

Allecra Therapeutics, a biopharma company developing novel therapies to combat antibiotic resistance, has received FDA approval for its treatment tackling ‘complicated’ urinary tract infections (UTIs).

PTC Therapeutics, Inc. Investigated by Shareholder Rights Advocates ... - Vimarsana News

PTC Therapeutics, Inc. Investigated by Shareholder Rights Advocates ...

PTC Therapeutics, Inc. Investigated by Shareholder Rights Advocates ...

The Ilocos Way: Unveiling best practices for dengue prevention - Vimarsana News

The Ilocos Way: Unveiling best practices for dengue prevention

Dengue, a relentless mosquito-borne disease, has emerged as a formidable global challenge, leaving no corner of the globe untouched. From bustling urban centers to remote rural areas, the impact of dengue is felt far and wide, as it continues to spread its insidious grip. 1 On a global scale, the…

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence - Vimarsana News

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial First opinion to be granted for an anti-PD-1/L1 therapy in resectable non-small...

Bavarian Nordic's Chikungunya Vaccine Candidate Granted - Vimarsana News

Bavarian Nordic's Chikungunya Vaccine Candidate Granted

Accelerated assessment allows for a shorter review period with EMA.Bavarian Nordic is on track to submit its Marketing Authorisation Application for...